Maarten Dewilde

Phagocytes as Plaque Catalysts: Human Macrophages Actively Generate Pathogenic Aβ42 Fibrils with Seeding and Cross-Seeding Potency

This study shows human macrophages and microglia actively produce Aβ42 fibrils, which seed amyloid plaques and tau aggregation, and this process is influenced by genetic factors like TREM2.

A pair of congenic mice for imaging of transplants by positron emission tomography using anti-transferrin receptor nanobodies

This paper develops a pair of congenic mice for PET/CT imaging of transplants using anti-TfR nanobodies, showing their ability to track transplanted cells without genetic modification.

The Alzheimer's therapeutic Lecanemab induces an amyloid-clearing program in microglia

This study shows Lecanemab reduces amyloid pathology by activating microglia through Fc fragment engagement, enhancing phagocytosis and lysosomal degradation.

Increasing brain half-life of antibodies by additional binding to myelin oligodendrocyte glycoprotein, a CNS specific protein

This paper demonstrates that binding antibodies to myelin oligodendrocyte glycoprotein (MOG) significantly increases their brain half-life when combined with transferrin receptor (TfR) mediated transport.

Single-molecule characterisation of soluble beta-amyloid aggregate binding by Aducanumab, Lecanemab, Gantenerumab, and Donanemab

The paper uses single-molecule detection and super-resolution imaging to analyze how four monoclonal antibodies bind to beta-amyloid aggregates, finding Lecanemab has superior binding properties.

Microfluidic interfaces for chronic bidirectional access to the brain.

This paper develops microfluidic interfaces for chronic fluid access to the brain in mice, enabling precise injection and long-term sampling of CSF and biomarkers.

In silico design of stable single-domain antibodies with high affinity

This paper introduces EvolveX, a computational pipeline for designing stable single-domain antibodies with high affinity, demonstrating improved binding affinity to human targets.

AAV mediated delivery of a novel anti-BACE1 VHH reduces Abeta in an Alzheimer’s disease mouse model

The paper demonstrates that AAV-delivered VHH-B9 reduces amyloid beta levels in an Alzheimer’s disease mouse model.